NVO Stock Novo Nordisk A/S
US · NYSELast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Leading metabolic franchise remains attractive after valuation compression and continued obesity-market expansion.
Future value: $45.75 (+17.17%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Depressed valuation, obesity pipeline catalysts, and improving institutional interest.
- ▾Below 50-day MA (-6.82%)
- ▾Near 52-week low (13.5% of range)
Is NVO a buy right now?
Trend: NVO is trading below the 50-day average (-6.32%), RSI 23 — oversold territory, with a 3-month return of -23.21%.
Valuation & quality: Novo Nordisk A/S trades on a trailing P/E of 9.6, forward P/E 11.4, PEG 4.36, price-to-book 5.21; fundamentals show net margin 35.3%, return on equity 59.8%, revenue growth 2.1% year on year.
Analyst consensus: 12 analysts have a mean 12-month price target of $45.03 (+15.1% vs the last close; range $39.69 – $61.70), consensus rating “hold”.
Income: trailing dividend yield 4.60%.
Our screen: ACCUMULATE (score 1) — Leading metabolic franchise remains attractive after valuation compression and continued obesity-market expansion.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -1.90% | +14.90% | +8.00% | +5.20% | -1.80% | -3.70% | -16.40% | +3.20% |
Fundamentals
Analyst price target
Technical signals
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Sector: Healthcare · Industry: Drug Manufacturers - General · Denmark · 66,700 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.